#dostarlimab search results
BREAKING: The #FDA has approved #dostarlimab in combination with chemotherapy for the treatment of patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. #gyncsm ow.ly/rc1350PpjF7
Dr. Erica Mayer (@elmayermd) presents results from the TBCRC 056 phase II study of neoadjuvant #Niraparib with #Dostarlimab for Patients with BRCA- or PALB2-Mutated #BreastCancer in the #SABCS24 Rapid Fire Session.
Paper 10: Phase 3 RUBY trial shows benefit of adding PD-1 inhibitor #dostarlimab to carboplatin and paclitaxel in patients with primary advanced or recurrent #endometrial cancer. In dMMR–MSI-H cohort, 2-year PFS: 61.4% vs 15.7% (HR 0.28). @NEJM nejm.org/doi/full/10.10…
@AndreaCercek update of Abs LBA 3512 #Dostarlimab use in MSI-H early stage #rectalcancer #cancer @asco #ASCO24 @GSKUS 👏👏👏 🔵 N=42 🔵 💯 cCR
What is a paper on #Dostarlimab and cancer treatment doing in a Journal titled "Biosensors"? As far as I could see the work had little to do with Biosensors. FYI I know about both the fields @MDPIOpenAccess
⭐Research highlight: In a phase 2 trial, complete responses to #neoadjuvant #dostarlimab allowed most patients with early-stage mismatch repair-deficient solid tumors to avoid surgery, allowing preservation of affected organs. @NEJM nature.com/articles/d4159…
Combination of #niraparib plus #dostarlimab in patients with #PleuralMesothelioma and #NSCLC with HRR-mutations lacks antitumor activity. Passiglia et al ID a novel predictor of clinical response. bit.ly/3vGFUmX @PassigliaFra @lullirighi @alisti878 @merlini_ale
UK woman declared cancer-free, thanks to #dostarlimab ethealthworld.com/s/bbttmg3 # via @ETHealthWorld
📣 Nouvel accès précoce #Dostarlimab « en combinaison avec une chimiothérapie à base de sels de platine pour le traitement des patientes adultes atteintes de cancer de l’endomètre avancé nouvellement diagnostiqué ou récidivant et candidates à un traitement systémique
Recently published: Phase II Study Evaluating the Efficacy of #Niraparib and #Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (#HNSCC) Patients, by Olga Zamulko et al. doi.org/10.1158/2767-9… @TMWiseDraper @uofcincy #OpenAccess
The #FDA has granted an expanded approval to #dostarlimab-gxly plus #chemotherapy for adult patients with primary advanced or recurrent #endometrial #cancer. Learn more about the #approval and the trial that led to it here: oncdata.com/dostarlimab-gx…
Neoadjuvant dostarlimab shows promise in a phase 2 trial, eliminating surgery for many with stage I-III dMMR solid tumors. Revolutionary! #Oncology #Dostarlimab PMID:40293177, N Engl J Med 2025, @NEJM doi.org/10.1056/NEJMoa… #AI #Pharma #BioMed #RNA #ASHG #ESHG
🔥FDA Alert: FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy oncologytube.com/fda-expands-en… #EndometrialCancer #Dostarlimab #FDAApproval #Oncology #CancerTreatment #Chemotherapy #GSK #ClinicalTrials #RUBYTrial #Immunotherapy #CancerResearch…
📺 Dr. @Sam_Cytryn of @MSKCancerCenter highlights how new data—including the recent @NEJM study on neoadjuvant #dostarlimab—underscore the exceptional sensitivity of MSI-high gastric cancers to immune checkpoint blockade: buff.ly/hECLHTQ
進行非小細胞 #肺がん の1次治療として、抗PD-1抗体 #dostarlimab と化学療法の併用療法は良好な効果を示す可能性が明らかになりました。ペムブロリズマブと化学療法の併用より全生存期間は延長傾向がありました。 #SITC2024 medical.nikkeibp.co.jp/leaf/all/cance…
medical.nikkeibp.co.jp
進行非小細胞肺癌の1次治療でdostarlimabと化学療法の併用は良好な効果を示す可能性、ペムブロリズマブ＋化学療法よりもOSの延長傾向が維持【SITC 2024】
進行非小細胞肺癌（NSCLC）の1次治療として、抗PD-1抗体dostarlimabと化学療法の併用療法は、想定外の安全性に関する問題もなく良好な効果を示す可能性が明らかになった。dostarlimabと化学療法の併用とペムブロリズマブと化学療法の併用を比較した無作為化フェーズ2試験であるPERLA試験（NCT04581824…
DOSTARLIMAB: It's the start of Gynae-Oncology Awareness Month - we have lots of information for you to support and educate you, whether patient or clinician. Why not find out more about Dostarlimab in the treatment of #ENDOMETERIALCANCER #womb #dostarlimab @GSK DOSTARLIMAB IN…
米国婦人科腫瘍学会からの速報です。進行・再発 #子宮体癌 の1次治療として、#dostarlimab と化学療法の併用は、化学療法単独と比べて全生存期間を有意に延長できることが分かりました。免疫療法の有意なOS延長効果が全体集団で示されたのは今回が初めてです。 #SGOMtg medical.nikkeibp.co.jp/leaf/all/cance…
#Jemperli Injection is a breakthrough #immunotherapy medicine containing #Dostarlimab, a programmed death receptor-1 (PD-1) blocking antibody that enhances the body’s immune response against #cancer cells. drugsgeneral.com/jemperli-injec…
Today’s blog will dive into #dostarlimab’s #anticancer mechanism and which cancer types may benefit from it. We’ll also explore some potential natural alternatives and/or complements to dostarlimab. Read on to learn more. anticancer360.com/does-dostarlim…
Today’s blog will dive into #dostarlimab ’s #anticancer mechanism and which cancer types may benefit from it. We’ll also explore some potential natural alternatives and/or complements to dostarlimab. Read on to learn more. anticancer360.com/does-dostarlim…
Neoadjuvant dostarlimab shows promise in a phase 2 trial, eliminating surgery for many with stage I-III dMMR solid tumors. Revolutionary! #Oncology #Dostarlimab PMID:40293177, N Engl J Med 2025, @NEJM doi.org/10.1056/NEJMoa… #AI #Pharma #BioMed #RNA #ASHG #ESHG
Today’s blog will dive into dostarlimab’s #anticancer mechanism and which #cancer types may benefit from it. We’ll also explore some potential natural alternatives and/or complements to #dostarlimab. Read on to learn more. anticancer360.com/does-dostarlim…
⭐Research highlight: In a phase 2 trial, complete responses to #neoadjuvant #dostarlimab allowed most patients with early-stage mismatch repair-deficient solid tumors to avoid surgery, allowing preservation of affected organs. @NEJM nature.com/articles/d4159…
Recently published: Phase II Study Evaluating the Efficacy of #Niraparib and #Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (#HNSCC) Patients, by Olga Zamulko et al. doi.org/10.1158/2767-9… @TMWiseDraper @uofcincy #OpenAccess
📺 Dr. @Sam_Cytryn of @MSKCancerCenter highlights how new data—including the recent @NEJM study on neoadjuvant #dostarlimab—underscore the exceptional sensitivity of MSI-high gastric cancers to immune checkpoint blockade: buff.ly/hECLHTQ
14 out of 14 patients cancer free on immune therapy #Dostarlimab
"Tumors just vanished, in all 14 consecutive patients" Groundbreaking cancer research. Dr Andrea Cerceck, lead researcher, used immunotherapy, monoclonal antibodies (for mismatch repair deficient, dMMR) helping every single patient avoid radiation. Dr Andrea Cercek: "We've…
Today’s blog will dive into dostarlimab’s #anticancer mechanism and which #cancer types may benefit from it. We’ll also explore some potential natural alternatives and/or complements to #dostarlimab. Read on to learn more. anticancer360.com/does-dostarlim…
If your tumor has the right genetic signature, your immune system may be all you need. “92% of patients treated with immunotherapy alone showed no signs of cancer two years later..." time.com/7280610/cancer… #immunotherapy #dostarlimab #cancerbreakthrough #nonsurgicaltreatment
2. IO (#dostarlimab) in neoadj (Stg I-III) dMMR solid tumors that were amendable to curative intent surgery by @AndreaCercek - RFS at 2yrs: 92% - 60% with Gr 1-2 reversible AEs and 30% with no AEs - Role of ctDNA? - NeoAdj IO led to organ preservation in a ⬆️ proportion 3/5
Among dMMR solid tumors, 82% had complete clinical response with PD-1 blockade. Utility of ctDNA dynamics shown.
Thank you @AndreaCercek @MSKCancerCenter @UCSFHospitals @KVanLoonMD 1 year Ned for me. Your work saved my life. Onward. #dostarlimab #rectalcancer #getscreened
Congratulations to our team. Next chapter in Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NE…
Big win for early-stage cancer patients! New study shows #Dostarlimab can eliminate tumours — most patients avoided surgery altogether. Incredible progress for #Immunotherapy and real hope for the future! #TCSC #CancerResearch #Hope abcnews.go.com/US/immunothera…
Revolutionary Immunotherapy Offers New Hope for Cancer Patients #cancertreatment #immunotherapy #dostarlimab #MemorialSloanKettering breakingon.com/health/revolut…
breakingon.com
Revolutionary Immunotherapy Offers New Hope for Cancer Patients
A new study shows that the immunotherapy drug dostarlimab can lead to complete tumor disappearance in cancer patients, challenging traditional treatment methods.
Minister Fleur Agema heeft besloten de nieuwe immuuntherapie #dostarlimab (merknaam: Jemperli®) vanaf nu tot eind 2026 te vergoeden vanuit het basispakket van de zorgverzekering. cefw.short.gy/mTegGH
Dr. Erica Mayer (@elmayermd) presents results from the TBCRC 056 phase II study of neoadjuvant #Niraparib with #Dostarlimab for Patients with BRCA- or PALB2-Mutated #BreastCancer in the #SABCS24 Rapid Fire Session.
BREAKING: The #FDA has approved #dostarlimab in combination with chemotherapy for the treatment of patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. #gyncsm ow.ly/rc1350PpjF7
A monumental breakthrough as #cancer vanishes for all patients in a new drug trial. 18 patients took a drug called #Dostarlimab for around six months, and after the trial, the cancer in the patients' bodies was and remains undetectable. Read more: khaleejtimes.com/health/cancer-…
Paper 10: Phase 3 RUBY trial shows benefit of adding PD-1 inhibitor #dostarlimab to carboplatin and paclitaxel in patients with primary advanced or recurrent #endometrial cancer. In dMMR–MSI-H cohort, 2-year PFS: 61.4% vs 15.7% (HR 0.28). @NEJM nejm.org/doi/full/10.10…
#Dostarlimab #upsc #cse #whyinnews #world #drug #wonderdrug #cancer #medication #lab #jemperli #antibodies #cancerpatients
PhII of pts w/stage II-III #crcsm (most LN+) w/dMMR with 100% cCR rate! to neoadjuvant #PD1 blockade #dostarlimab allowing pts to avoid chemoRT and surgery. New paradigm in #MSIH locally adv #rectal adenoCA - all #MSIH pts in this setting need neoadjuvant #IO @ASCO #GI22
अमेरिका में #Cancer के 18 मरीजों पर एक नई दवा का ट्रायल हुआ है. इसमें शामिल सभी मरीज पूरी तरह ठीक हो गए. आम तौर पर कैंसर के गंभीर मरीजों में इलाज के बाद दोबारा कैंसर सेल्स पनपने की संभावना बनी रहती है. लेकिन इस ट्रायल में ऐसा नहीं हुआ. #Dostarlimab thelallantop.com/lallankhas/pos…
Phenomenal 100% complete clinical response rate for 14 consecutive locally advanced #rectalcancer by #dostarlimab presented by @AndreaCercek @MSKCancerCenter published @NEJM #ASCO2022 On our way to practice-changing non-operative organ-sparing management in #lynchsyndrome
A new PD-1 antagonist, #dostarlimab, receives EU approval for use in some endometrial cancers. ms.spr.ly/6013V8MnV
#Dostarlimab #upsc #cse #whyinnews #world #drug #wonderdrug #cancer #medication #lab #jemperli #antibodies #cancerpatients
Clearing the mist around the wonder drug #Dostarlimab. Yes! It is undoubtedly a sign of hope, but we must wait for the long-term data and its cost-effectiveness. Perspective covered in today’s @DeccanChronicle #CancerCare #AIGCares #Immunotherapy
@AndreaCercek update of Abs LBA 3512 #Dostarlimab use in MSI-H early stage #rectalcancer #cancer @asco #ASCO24 @GSKUS 👏👏👏 🔵 N=42 🔵 💯 cCR
أذهلت نتائج اختبارات علاج جديد للسرطان يدعى "#Dostarlimab" العلماء الذين أشرفوا على تجربة حديثة، إذ تماثل للشفاء جميع المرضى الذين شاركوا في التجربة؛ في حدث جديد لم يعهده المجتمع العلمي من قبل.
Something went wrong.
Something went wrong.
United States Trends
- 1. Good Sunday 57.8K posts
- 2. Klay 25K posts
- 3. McLaren 105K posts
- 4. #sundayvibes 4,572 posts
- 5. Lando 137K posts
- 6. #FelizCumpleañosPresidente 3,116 posts
- 7. #FelizCumpleañosNico 3,366 posts
- 8. For the Lord 30K posts
- 9. #AEWFullGear 73K posts
- 10. Ja Morant 11.4K posts
- 11. Oscar 128K posts
- 12. Tottenham 41.3K posts
- 13. Piastri 77.5K posts
- 14. #LasVegasGP 232K posts
- 15. Verstappen 106K posts
- 16. Childish Gambino 2,701 posts
- 17. South Asia 38.5K posts
- 18. Arsenal 165K posts
- 19. Swerve 6,884 posts
- 20. God Bless America 6,975 posts